<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of osteonecrosis (avascular necrosis of bone)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of osteonecrosis (avascular necrosis of bone)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of osteonecrosis (avascular necrosis of bone)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynne C Jones, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael A Mont, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Simon M Helfgott, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Collins, MD, PhD, FACS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 26, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2457513603">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteonecrosis, also known as aseptic necrosis, avascular necrosis (AVN), atraumatic necrosis, and ischemic necrosis, is a pathologic process that is associated with numerous conditions and therapeutic interventions. The cause is clearly identifiable in patients who have direct damage to bone vasculature (eg, femoral neck fracture) or direct injury of bone or marrow elements (eg, radiation injury, dysbarism, or decompression disease). However, in many patients, the mechanisms by which this disorder develops are not fully understood.
        </p>
        <p>
         Reduced perfusion leading to ischemia and eventual death of bone and marrow cells (bone marrow infarction) and ultimate mechanical failure appears to be common to most proposed etiologies. The process is most often progressive, resulting in joint destruction within a few months to several years in the majority of patients [
         <a href="#rid1">
          1,2
         </a>
         ]. The femoral head is the most commonly affected site, but osteonecrosis can develop in other locations including the distal femur, humeral head, and small bones of the wrist and foot.
        </p>
        <p>
         Two types of osteonecrosis are limited to children: idiopathic osteonecrosis of the femoral head (Legg-Calvé-Perthes disease) and osteonecrosis occurring in children, usually adolescents, with a slipped capital femoral epiphysis. The differences in the natural history of adult osteonecrosis and the juvenile forms may reflect differences in the pathogenesis and natural history of these diseases. These diseases are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2856.html" rel="external">
          "Approach to hip pain in childhood", section on 'Legg-Calvé-Perthes and secondary avascular necrosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6554.html" rel="external">
          "Evaluation and management of slipped capital femoral epiphysis (SCFE)", section on 'Osteonecrosis'
         </a>
         .)
        </p>
        <p>
         The clinical manifestations and diagnosis of osteonecrosis in adults will be reviewed here. The treatment of this disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5613.html" rel="external">
          "Treatment of nontraumatic hip osteonecrosis (avascular necrosis of the femoral head) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H256491200">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The exact prevalence of osteonecrosis is unknown. In the United States, there are an estimated 10,000 to 20,000 patients newly diagnosed each year [
         <a href="#rid3">
          3
         </a>
         ], with even larger numbers worldwide, and it is the underlying diagnosis in approximately 10 percent of all total hip replacements (THR) in the United States [
         <a href="#rid4">
          4
         </a>
         ]. The male-to-female ratio varies depending upon the associated comorbidities. For example, alcohol-associated osteonecrosis is more common in men, while osteonecrosis associated with systemic lupus erythematosus (SLE) is more common in females. The mean age at diagnosis also depends upon comorbidities but is typically less than 50 years [
         <a href="#rid5">
          5-7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3387049048">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of osteonecrosis is an area of controversy. Most experts believe that it is the result of the combined effects of genetic predisposition, metabolic factors, and local factors affecting blood supply, such as vascular injury, increased intraosseous pressure, and mechanical stresses [
         <a href="#rid4">
          4,8,9
         </a>
         ]. The early stages of the natural history are unclear, as these stages are largely asymptomatic and patients often do not present until later. It is generally agreed that there is an interruption of the blood circulation within the bone; subsequently, the adjacent area becomes hyperemic. During the natural history of osteonecrosis, it is often possible to identify a reparative zone enveloping the sequestrum (ie, a necrotic zone). The reparative zone has been characterized in early stages by sinusoidal congestion and hemorrhage [
         <a href="#rid10">
          10
         </a>
         ]. This is followed by "reactive angiogenesis," a process in which vasodilators released from the tissue surrounding the infarct, such as nitric oxide and vascular endothelial growth factor (VEGF), promote angiogenesis [
         <a href="#rid11">
          11,12
         </a>
         ]. However, the angiogenesis is often impaired, resulting in demineralization, followed by trabecular thinning, and, later, by collapse [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         The histopathologic finding of bone marrow infarction has been noted in marrow samples from patients with some of the same disorders that cause clinically apparent osteonecrosis [
         <a href="#rid14">
          14
         </a>
         ]. However, other etiologies for bone marrow infarction include neoplastic disorders, particularly hematologic and lymphoid malignancies and metastatic cancer with associated coagulopathy. The causes of bone marrow infarction (bone marrow necrosis) are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4434.html" rel="external">
          "Evaluation of bone marrow aspirate smears", section on 'Bone marrow necrosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H878671233">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of traumatic and atraumatic factors contribute to the etiology of osteonecrosis. A definitive etiologic role has been established for some of these factors, based upon longitudinal cohort studies or meta-analyses, but not for the majority, which are considered associated risk factors [
         <a href="#rid15">
          15
         </a>
         ]. The use of glucocorticoids and excessive alcohol intake are associated with more than 80 percent of atraumatic cases [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2137068930">
         <span class="h2">
          Medications and drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both prescribed medications and alcohol have been implicated as causes of osteonecrosis.
        </p>
        <p class="headingAnchor" id="H1775522847">
         <span class="h3">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous studies relate the use of systemic glucocorticoids to the development of osteonecrosis. In one study of 1199 joints in 302 patients, the incidence of developing osteonecrosis as a consequence of systemic glucocorticoids ranged from 21 to 37 percent [
         <a href="#rid16">
          16
         </a>
         ]; the frequency varied, depending, in part, upon the associated comorbidities, duration, and dose [
         <a href="#rid16">
          16-18
         </a>
         ].
        </p>
        <p>
         Although the pathogenesis of glucocorticoid-associated osteonecrosis has not been established, there are several mechanisms that have been proposed [
         <a href="#rid15">
          15,19
         </a>
         ]. One possible mechanism involves alterations in circulating lipids with resultant microemboli in the arteries supplying bone [
         <a href="#rid20">
          20
         </a>
         ]. Another potential mechanism is that an increase in bone marrow adipocyte size and number within the bone marrow compartment of convex joints contributes to blocking venous outflow resulting in increased intraosseous pressure [
         <a href="#rid21">
          21
         </a>
         ]. Yet another theory proposes that glucocorticoids induce changes in venous endothelial cells, leading to stasis, increased intraosseous pressure, and eventual necrosis [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Patients treated with prolonged high doses of systemic glucocorticoids appear to be at the greatest risk of developing osteonecrosis, but these patients often have multiple other risk factors [
         <a href="#rid23">
          23,24
         </a>
         ]. Patients receiving chronic physiologic glucocorticoid replacement for adrenal insufficiency may develop osteonecrosis (2.4 percent in one report) [
         <a href="#rid25">
          25
         </a>
         ]. However, osteonecrosis generally does not result from short-term use of these medications. In previous anecdotal reports suggesting an association, multiple additional risk factors were also present, suggesting that it was highly unlikely that these low doses led to the disease [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Most studies have found that the risk is low (less than 3 percent) in patients treated with doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         less than 15 to 20 mg/day. A population-based study identified 98,390 patients who had received a single short-term, low-dose
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         taper pack (MTP) prescription and found that the incidence of osteonecrosis among this group of patients was only 0.13 percent [
         <a href="#rid27">
          27
         </a>
         ]. However, compared with patients who had not received an MTP, the relative risk was 1.60 (95% CI 1.34-1.84). In a small series of systemic lupus erythematosus (SLE) patients exposed to higher doses of glucocorticoids, the prednisone dose in the highest month of therapy exceeded 40 mg/day in 93 percent and 20 mg/day in 100 percent of patients with osteonecrosis [
         <a href="#rid28">
          28
         </a>
         ]. The only clinical finding that distinguished patients with osteonecrosis from those without this complication was a Cushingoid appearance (86 versus 15 percent).
        </p>
        <p>
         The initial glucocorticoid dose may be more important than the total dose or duration of therapy [
         <a href="#rid26">
          26,29
         </a>
         ]. A meta-analysis of seven studies including 1515 patients taking systemic glucocorticoids found a dose-dependent association between glucocorticoid use and the risk of developing osteonecrosis [
         <a href="#rid26">
          26
         </a>
         ]. Each 10 mg/day increase in glucocorticoid dose was associated with a 3.6 percent increase in the risk of osteonecrosis, and doses &gt;20 mg/day resulted in a higher incidence. Another report evaluated 17 patients with SLE who developed osteonecrosis [
         <a href="#rid30">
          30
         </a>
         ]. The glucocorticoid dose during the initial period of therapy was compared with that of 25 control patients with SLE. The patients with osteonecrosis had received a substantially higher dose of glucocorticoid in the first one, three, and six months of therapy. By comparison, the duration of therapy did not correlate with osteonecrosis, and total glucocorticoid exposure was virtually identical in both groups.
        </p>
        <p>
         Osteonecrosis has been described as a rare complication of intraarticular glucocorticoid injections and is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7977.html" rel="external">
          "Joint aspiration or injection in adults: Complications", section on 'Osteonecrosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2658947496">
         <span class="h3">
          Bisphosphonates and other antiresorptive agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of bisphosphonates, particularly in patients with malignant diseases such as multiple myeloma and metastatic breast cancer, is a risk factor for osteonecrosis of the jaw. This disorder has been likened to radiation-induced osteonecrosis of the jaw and presents with nonhealing of the socket following tooth extraction or exposure of the jaw bone. Osteonecrosis of the jaw associated with bisphosphonate use, as well as use of other antiresorptive agents (eg,
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         ), is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2806.html" rel="external">
          "Risks of therapy with bone antiresorptive agents in patients with advanced malignancy", section on 'Osteonecrosis of the jaw'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">
          "Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Osteonecrosis of the jaw'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3763318911">
         <span class="h3">
          Alcohol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excessive alcohol use and the development of osteonecrosis have long been linked; fat emboli, adipocyte hypertrophy, venous stasis, and increased cortisol levels have all been implicated as etiologic factors. While only a small percentage of patients with alcohol use disorder develop osteonecrosis, excessive alcohol intake has been considered an associated risk factor in up to 31 percent of the osteonecrosis patients evaluated [
         <a href="#rid5">
          5,31-33
         </a>
         ]. One epidemiologic study compared 112 patients who had idiopathic osteonecrosis of the femoral head and no history of systemic glucocorticoid use with 168 hospital controls [
         <a href="#rid31">
          31
         </a>
         ]. An elevated risk for regular drinkers and a clear dose-response relationship were noted; the relative risk was 3.3, 9.8, and 17.9 for current consumers of less than 400 mL/week, 400 to 1000 mL/week, and more than 1000 mL/week of alcohol, respectively, compared with controls.
        </p>
        <p class="headingAnchor" id="H159814767">
         <span class="h2">
          Cigarette smoking
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cigarette smoking has been implicated as a risk factor for osteonecrosis of the femoral head in a dose-dependent manner [
         <a href="#rid34">
          34
         </a>
         ]. However, it is difficult to assess the true risk of tobacco use due to its close association with, and the potential confounding effect of, alcohol intake.
        </p>
        <p class="headingAnchor" id="H535469537">
         <span class="h2">
          Post-transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteonecrosis has been reported to occur in approximately 5 to 20 percent of renal transplantation patients [
         <a href="#rid35">
          35,36
         </a>
         ]. Osteonecrosis is usually multifocal when it occurs following renal transplantation [
         <a href="#rid37">
          37
         </a>
         ], with 50 to 70 percent of affected patients having more than one joint involved [
         <a href="#rid38">
          38
         </a>
         ]. However, a decreased risk of osteonecrosis in renal transplant patients has been shown to occur following the introduction of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         (with consequent decreases in glucocorticoid dosing) [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7299.html" rel="external">
          "Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation"
         </a>
         .)
        </p>
        <p>
         It is unclear whether osteopenia and preexisting hyperparathyroidism are independent risk factors in the renal transplantation population [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2043.html" rel="external">
          "Prevention and treatment of osteoporosis after solid organ or stem cell transplantation"
         </a>
         .)
        </p>
        <p>
         Osteonecrosis may also occur with other types of transplantation, such as hematopoietic cell transplantation (HCT). Osteonecrosis has been reported to occur in 4 to 19 percent of HCT survivors [
         <a href="#rid42">
          42
         </a>
         ], with a mean time from HCT transplantation to diagnosis of osteonecrosis of 15 months (range 5 to 48) [
         <a href="#rid43">
          43
         </a>
         ]. As an example, one study surveyed the prevalence of osteonecrosis among 207 patients undergoing HCT for lymphoproliferative or myeloproliferative diseases [
         <a href="#rid44">
          44
         </a>
         ]. Patients receiving allogeneic HCT were more often affected than those receiving autologous HCT (10 versus 2 percent). The duration and cumulative dose of glucocorticoids, as well as the presence of graft-versus-host disease, were risk factors for the development of this complication [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
         Among allogeneic HCT recipients, the risk of osteonecrosis may also depend upon the sex of the donor and the recipient, as well as the disease for which HCT is being performed. This was illustrated in a study of 255 patients who underwent allogeneic HCT for one of a variety of hematologic disorders and were evaluated for osteonecrosis of the hip [
         <a href="#rid46">
          46
         </a>
         ]. The following risk factors were noted in addition to glucocorticoid exposure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The overall incidence of osteonecrosis of the hip was 6 percent during four years of post-transplant observation, but there were no cases among the 152 patients transplanted for chronic myeloid leukemia. The incidence in the remaining patients was 20 percent (13 percent of 70 patients with acute myeloid leukemia, 28 percent of 13 patients with myelodysplastic disorders, and 37 percent of 20 patients with acute lymphoblastic leukemia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Female donor to female recipient transplantation carried the highest risk of osteonecrosis, with more than 40 percent of such patients underwent subsequent hip replacement for osteonecrosis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2494288226">
         <span class="h2">
          Systemic lupus erythematosus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteonecrosis has been reported in 3 to 44 percent of patients with SLE [
         <a href="#rid30">
          30,47-49
         </a>
         ]. This wide range reflects the use of different techniques in defining this disorder (from the less sensitive plain film radiograph to the quite sensitive magnetic resonance imaging [MRI]), variations in glucocorticoid dosing, and different durations of follow-up. One report followed 228 patients with SLE for a mean period of 31 months. Nine percent had osteonecrosis, and it was estimated that the frequency would rise to 30 percent at 10 to 15 years [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Patients with SLE who have taken glucocorticoids are at greatest risk, although occasional cases have been noted in the absence of this therapy [
         <a href="#rid30">
          30,47,50
         </a>
         ]. Osteonecrosis often develops in patients with SLE a relatively short time after the onset of glucocorticoid therapy. One prospective study, for example, evaluated 60 patients with SLE over a period of five years [
         <a href="#rid50">
          50
         </a>
         ]. Those who had no MRI abnormalities in the femoral head during the first year of follow-up were unlikely to develop osteonecrosis at a later date. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
         Other risk factors for osteonecrosis have also been identified in SLE. These include regular doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         greater than 20 mg/day, evidence of glucocorticoid-associated end organ effect, Raynaud phenomenon, and hyperlipidemia [
         <a href="#rid51">
          51
         </a>
         ]. Additional associations have been suggested [
         <a href="#rid51">
          51,52
         </a>
         ], including the presence of antiphospholipid antibodies, African-American origin, Cushingoid habitus, vasculitis, pleuritis, and central nervous system (CNS) involvement.
        </p>
        <p>
         There are conflicting data on the role of antiphospholipid antibodies in SLE; some data support an association [
         <a href="#rid52">
          52,53
         </a>
         ], while other data do not [
         <a href="#rid54">
          54
         </a>
         ]. As an example, in a study of 45 patients who had osteonecrosis, only nine of whom had SLE [
         <a href="#rid55">
          55
         </a>
         ], the prevalence of antiphospholipid antibodies was more than threefold greater among the 45 patients with osteonecrosis compared with 40 healthy controls (34 versus 10 percent). In a study of multifocal osteonecrosis patients, antiphospholipid antibody positivity was detected in 20 percent of cases [
         <a href="#rid56">
          56
         </a>
         ]. However, as with patients with SLE, not all data regarding the risk of osteonecrosis in patients with primary antiphospholipid syndrome are concordant, suggesting, at best, a weak association [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">
          "Clinical manifestations of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1662658951">
         <span class="h2">
          Trauma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fracture or dislocation may cause damage to the extraosseous blood vessels supplying the affected region. Anatomic sites that predispose adjacent bone to avascular necrosis (AVN) after fracture include the femoral neck, proximal humerus, talar neck, and scaphoid [
         <a href="#rid58">
          58
         </a>
         ]. Dislocation of the proximal femur or humerus can also result in osteonecrosis if reduction is delayed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The blood supply to the femoral neck is complex, with the dominant supply from the ascending branch of the medial femoral circumflex artery  (
         <a class="graphic graphic_figure graphicRef72956" href="/z/d/graphic/72956.html" rel="external">
          figure 1
         </a>
         ). Fractures in the subcapital region of the femoral neck frequently interrupt the blood supply to the head of the femur due to fracture displacement or intracapsular hematoma [
         <a href="#rid58">
          58
         </a>
         ]. This can result in ischemia and bone necrosis. In a meta-analysis including 1558 femoral neck fractures in patients 60 years or younger, the pooled incidence of osteonecrosis was 14.3 percent [
         <a href="#rid59">
          59
         </a>
         ]. The incidence was higher for displaced versus nondisplaced fractures (14.7 versus 6.4 percent). Symptoms develop six months to two years after injury, but the presentation can be delayed even longer. (See
         <a class="medical medical_review" href="/z/d/html/226.html" rel="external">
          "Overview of common hip fractures in adults", section on 'Femoral neck fractures'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Damage to the anterior and/or posterior humeral circumflex artery  (
         <a class="graphic graphic_figure graphicRef71903" href="/z/d/graphic/71903.html" rel="external">
          figure 2
         </a>
         ) can occur with typical fracture patterns of the proximal humerus  (
         <a class="graphic graphic_figure graphicRef67578" href="/z/d/graphic/67578.html" rel="external">
          figure 3
         </a>
         ). Osteonecrosis occurs in 1 to 10 percent of such fractures [
         <a href="#rid58">
          58
         </a>
         ]. In a systematic review, the rate of osteonecrosis was similar for surgically and nonsurgically managed proximal humerus fractures [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/217.html" rel="external">
          "Proximal humeral fractures in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6540.html" rel="external">
          "Proximal humeral fractures in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perforator vessels enter the talus in three locations with contributions from each of the tibial arteries (anterior tibial, posterior tibial, peroneal)  (
         <a class="graphic graphic_figure graphicRef65590" href="/z/d/graphic/65590.html" rel="external">
          figure 4
         </a>
         ). The majority of cases of osteonecrosis occur after talar neck fractures (90 percent), although it has been reported after talar body fractures as well. The incidence of osteonecrosis correlates with the fracture severity (Hawkins type  (
         <a class="graphic graphic_figure graphicRef53096" href="/z/d/graphic/53096.html" rel="external">
          figure 5
         </a>
         )) ranging from 0 to 10 percent for low-grade (type I/II) and 33 to 48 percent for type IV fractures, depending on the version of the classification used [
         <a href="#rid58">
          58,61,62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/82957.html" rel="external">
          "Talus fractures"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At the wrist  (
         <a class="graphic graphic_figure graphicRef69097" href="/z/d/graphic/69097.html" rel="external">
          figure 6
         </a>
         ), fractures of the scaphoid and lunate are also associated with an increased risk of osteonecrosis. The dorsal carpal branch of the radial artery can be disrupted with scaphoid waist and proximal pole fractures. (See
         <a class="medical medical_review" href="/z/d/html/197.html" rel="external">
          "Scaphoid fractures"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2381589131">
         <span class="h2">
          Genetic disorders
         </span>
        </p>
        <p class="headingAnchor" id="H1944264056">
         <span class="h3">
          Sickle cell hemoglobinopathies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteonecrosis is common in patients with homozygous sickle cell disease due to various mechanisms, including red blood cell sickling, and bone marrow hyperplasia. The reported prevalence of osteonecrosis of the femoral head in patients with sickle cell disease ranges from 10 to 50 percent [
         <a href="#rid63">
          63-65
         </a>
         ]. Patients with more severe sickle cell disease have a higher incidence compared with patients with less severe sickle cell disease (1.06 per 100 person-years) [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">
          "Overview of the clinical manifestations of sickle cell disease", section on 'Skeletal complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5919.html" rel="external">
          "Acute and chronic bone complications of sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3513017559">
         <span class="h3">
          Gaucher disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gaucher disease (GD) is a hereditary (autosomal recessive) disorder of glucocerebroside metabolism, which results in the accumulation of cerebroside-filled cells within the bone marrow. This process may lead to compression of the vasculature and to subsequent osteonecrosis. Bone pain has been reported to occur in 50 percent and osteonecrosis in 30 percent of type 1 GD patients [
         <a href="#rid66">
          66
         </a>
         ]. However, the introduction of enzyme replacement therapy (ERT) has been shown to decrease the rate of osteonecrosis in these patients [
         <a href="#rid67">
          67-69
         </a>
         ]. In a study using the International Collaborative Gaucher Group (ICGG) Registry, GD patients who initiated ERT within two years of diagnosis had a lower incidence rate (8.1 per 1000 person-years) compared with GD patients who started ERT ≥2 years after diagnosis (16.6 per 1000 person-years) [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2918.html" rel="external">
          "Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H960003086">
         <span class="h3">
          Heritable osteonecrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, osteonecrosis of the femoral head occurs as a heritable disorder. In one study of three affected Chinese families, mutations were present in the gene for the alpha chain of type II collagen (
         <em>
          COL2A1
         </em>
         ) [
         <a href="#rid70">
          70
         </a>
         ]. However, no mutations in the
         <em>
          COL2A1
         </em>
         gene were found in 65 patients who had sporadic osteonecrosis of the femoral head. Substitution of serine for glycine in a portion of the molecule that forms an extended triple helical portion was predicted to result from the observed mutations.
        </p>
        <p>
         The same
         <em>
          COL2A1
         </em>
         mutation described above can be associated with at least three different clinical presentations. This was observed in another Chinese family that included individuals with premature osteoarthritis, osteonecrosis of the femoral head, or idiopathic osteonecrosis of the femoral head (Legg-Calvé-Perthes disease), which were diagnosed, respectively, in young adults, adolescents, or children [
         <a href="#rid71">
          71
         </a>
         ]. Legg-Calvé-Perthes disease has also been reported in members of a Japanese family [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         It is important to distinguish between genetic associations found in adult osteonecrosis and secondary osteonecrosis (eg, glucocorticoid-associated) versus genetic association found for Legg-Calvé-Perthes disease. The pathogenetic mechanisms involved may differ between these disorders. (See
         <a class="medical medical_review" href="/z/d/html/2856.html" rel="external">
          "Approach to hip pain in childhood", section on 'Legg-Calvé-Perthes and secondary avascular necrosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6554.html" rel="external">
          "Evaluation and management of slipped capital femoral epiphysis (SCFE)", section on 'Osteonecrosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2266724396">
         <span class="h3">
          Inherited thrombophilia and hypofibrinolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are some data from small retrospective series regarding the role of mutations in genes for proteins in the coagulation and fibrinolytic pathways in the pathogenesis of osteonecrosis. As an example, four reports suggest an increased prevalence of the factor V Leiden mutation in patients with osteonecrosis of the hip or knee compared with healthy controls [
         <a href="#rid73">
          73-76
         </a>
         ]. However, no significant association was observed between the frequencies of the factor V polymorphisms and haplotypes and the risk of osteonecrosis of the femoral head in a Korean population [
         <a href="#rid77">
          77
         </a>
         ]. As such, it is possible that there are variations in the association between genetic polymorphisms and osteonecrosis based on nationality or ethnicity. In another observational study including 45 patients with osteonecrosis, significantly more patients with osteonecrosis (82 percent) were found to have at least one coagulopathy compared with controls (30 percent) [
         <a href="#rid55">
          55
         </a>
         ]. In addition, 47 percent of patients with osteonecrosis had two or more coagulopathies, compared with 3 percent of controls. While there may be a relationship between inherited thrombophilias and osteonecrosis, there is insufficient evidence to warrant routine testing for such conditions in these patients. (See
         <a class="medical medical_review" href="/z/d/html/1355.html" rel="external">
          "Factor V Leiden and activated protein C resistance", section on 'Indications for testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2784605748">
         <span class="h2">
          Decompression disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The increased pressure associated with decompression disease (also called dysbarism and caisson disease) can lead to the formation of nitrogen bubbles that can occlude arterioles and cause osteonecrosis (see
         <a class="medical medical_review" href="/z/d/html/177.html" rel="external">
          "Complications of SCUBA diving", section on 'Decompression sickness'
         </a>
         ). Symptomatic osteonecrosis can develop years after the exposure; the number of exposures and the magnitude of depth and pressure are important risk factors. Elevated plasma levels of plasminogen activator inhibitor 1 (PAI-1) are associated with an increased risk of osteonecrosis [
         <a href="#rid78">
          78
         </a>
         ]. The incidence of dysbaric osteonecrosis has decreased over the past several decades with improvements in technology and increased awareness of this disorder [
         <a href="#rid79">
          79
         </a>
         ]. However, there is still a risk if the diagnosis is not timely and medical management is not optimal.
        </p>
        <p class="headingAnchor" id="H2080859047">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteonecrosis may result from external beam radiation therapy (osteoradionecrosis). Osteoradionecrosis of the mandible may complicate treatment of head and neck cancer. (See
         <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">
          "Management of late complications of head and neck cancer and its treatment", section on 'Osteoradionecrosis and soft tissue necrosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3596884793">
         <span class="h2">
          Other risk factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute lymphoblastic leukemia
         </strong>
         – Osteonecrosis is one of the most common adverse effects of antileukemic treatment among children [
         <a href="#rid80">
          80
         </a>
         ]. In a study of 10,729 new-onset acute lymphoblastic leukemia patients (age range, 2.02 to 21.23 years), 242 (2.3 percent) developed osteonecrosis within five years of their acute lymphoblastic leukemia diagnosis [
         <a href="#rid81">
          81
         </a>
         ]. Although the rate of osteonecrosis was lower in a large database study in Finland and Denmark (0.4 percent), there was also an association reported for patients with chronic myeloid leukemia (4.5 percent) and acute myeloid leukemia (2.1 percent) [
         <a href="#rid82">
          82
         </a>
         ]. Glucocorticoid therapy (
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ) is commonly used in the treatment of acute lymphoblastic leukemia, and it may increase the risk for osteonecrosis (particularly dexamethasone) [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">
          "Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV infection
         </strong>
         – The risk of developing osteonecrosis in patients with human immunodeficiency virus (HIV) infection has been reported to be 45 to 100 times greater than in the general population [
         <a href="#rid84">
          84,85
         </a>
         ]. In one case-control study, the point prevalence of osteonecrosis that was apparent on MRI was 4 percent among 339 HIV-infected patients, while no osteonecrosis was found in 118 sex- and age-matched healthy controls [
         <a href="#rid86">
          86
         </a>
         ]. There has been considerable debate concerning whether highly active antiretroviral therapy (HAART) is a risk factor for osteonecrosis [
         <a href="#rid85">
          85,87
         </a>
         ]. Glucocorticoid therapy is likely a risk factor for osteonecrosis and may be exacerbated by concurrent administration of protease inhibitors [
         <a href="#rid85">
          85,88
         </a>
         ]. Use of antiretroviral therapy (ART) does not appear to be an independent risk factor [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other risk factors for osteonecrosis of the knee include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postarthroscopic osteonecrosis of the knee
         </strong>
         – Osteonecrosis of the knee after arthroscopy is rare but has been described as occurring in up to 4 percent of patients after various arthroscopic procedures [
         <a href="#rid90">
          90
         </a>
         ]. The medial femoral condyle is the most commonly affected site, and typically the affected area coincides with the area of the preexisting pathology and arthroscopic procedure [
         <a href="#rid91">
          91
         </a>
         ]. Patients present with a sudden onset of knee pain approximately six to eight weeks after the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spontaneous osteonecrosis of the knee
         </strong>
         – Spontaneous osteonecrosis of the knee (SPONK or SONK) is a rare disorder of unknown cause that tends to occur in older adults and typically affects a single condyle (most commonly the medial femoral condyle) [
         <a href="#rid92">
          92
         </a>
         ]. Patients may present with a sudden onset of severe unilateral knee pain that is worse at night or with weight bearing.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H635536357">
         <span class="h1">
          CLINICAL FEATURES AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early diagnosis of osteonecrosis may provide the opportunity to prevent bony collapse and, ultimately, the need for joint replacement or other bone reconstruction. However, most patients present late in the course of the disease. Thus, a high index of suspicion is necessary for those with known or probable risk factors, particularly high-dose glucocorticoid use.
        </p>
        <p>
         Osteonecrosis usually occurs in the anterolateral femoral head, although it may also affect the femoral condyles, humeral heads, proximal tibia, vertebrae, and small bones of the hand and foot [
         <a href="#rid9">
          9
         </a>
         ]. Many patients have bilateral involvement at the time of diagnosis, including disease of the hips, knees, and shoulders. In patients who present with osteonecrosis of the knee, shoulder, or other non-hip joint, the hip should be evaluated clinically and by imaging. (See
         <a class="local">
          'Imaging studies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3327766569">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         A thorough history should include questions related to the various risk factors. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
         The most common presenting symptom of osteonecrosis is pain [
         <a href="#rid93">
          93,94
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Groin pain is most common in patients with femoral head disease, followed by thigh and buttock pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weightbearing or motion-induced pain is found in most cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pain in the absence of activity (ie, rest pain) occurs in approximately two-thirds of patients, and nocturnal pain occurs in one-third [
         <a href="#rid95">
          95
         </a>
         ]. When an extremity is affected, the position of the limb (eg, elevated, dependent) does not alter the pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although rare, pain in multiple joints suggests a multifocal process.
        </p>
        <p>
        </p>
        <p>
         A small proportion of patients are initially asymptomatic, particularly in early-stage disease; in these cases, the diagnosis is usually incidental. Asymptomatic involvement contralateral to a symptomatic site is also frequently noted.
        </p>
        <p>
         Physical findings are largely nonspecific. Patients may have pain and, eventually, limitations of range of motion, the severity of which depends on the affected joint and severity of disease. With hip disease, limitations eventually occur, particularly with internal rotation and abduction. A limp may be present late in the course of lower extremity disease [
         <a href="#rid8">
          8
         </a>
         ]. In the absence of concomitant vascular disease, the pulse examination should be normal.
        </p>
        <p class="headingAnchor" id="H2723469997">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A clinical diagnosis can be made in a symptomatic patient when radiographic imaging findings or MRI are compatible with this disease and when other causes of pain and bony abnormalities are either unlikely or have been excluded by appropriate testing. MRI without a contrast agent continues to be the "gold standard" for diagnosis in symptomatic and asymptomatic patients, especially in early-stage disease [
         <a href="#rid96">
          96,97
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3881414892">
         <span class="h3">
          Imaging studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation of a patient with suspected osteonecrosis should begin with plain radiographs of the affected anatomic site [
         <a href="#rid98">
          98
         </a>
         ]. For patients with suspected hip osteonecrosis, plain radiography should include anteroposterior and frog-leg lateral plain radiographs. If collapse of the hip is apparent, no further imaging is required for diagnosis. However, if the diagnosis of atraumatic osteonecrosis is suspected at a joint other than the hip, it is recommended that the hip joint also be imaged [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         MRI of the affected joint should be performed if radiographs are negative and the medical history supports a suspicion of osteonecrosis.
        </p>
        <p>
         Computed tomography (CT) scans have been used for the identification of subchondral fractures, a pathologic feature which may have prognostic value for joint-preserving procedures [
         <a href="#rid99">
          99
         </a>
         ]. However, improvements in MRI methods, cost, and the amount of radiation exposure deter the more frequent use of this imaging modality.
        </p>
        <p class="headingAnchor" id="H2882813621">
         <span class="h4">
          Plain radiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         The plain radiograph of any site affected by osteonecrosis can remain normal for months after symptoms begin; the earliest findings are mild density changes  (
         <a class="graphic graphic_diagnosticimage graphicRef79133 graphicRef69304" href="/z/d/graphic/79133.html" rel="external">
          image 1A-B
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef79910" href="/z/d/graphic/79910.html" rel="external">
          image 2
         </a>
         ), followed by sclerosis and cysts as the disease progresses.
        </p>
        <p>
         For osteonecrosis of the femoral head, the pathognomonic crescent sign (subchondral radiolucency  (
         <a class="graphic graphic_diagnosticimage graphicRef131110" href="/z/d/graphic/131110.html" rel="external">
          image 3
         </a>
         )) is evidence of subchondral collapse. Later stages reveal loss of sphericity or collapse of the femoral head. Ultimately, joint space narrowing and degenerative changes in the acetabulum are visible [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H789253468">
         <span class="h4">
          Magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI has a reported sensitivity of up to 100 percent for the diagnosis of osteonecrosis [
         <a href="#rid9">
          9,101-103
         </a>
         ]. Of particular importance is that changes can be seen early in the course of disease when radiographs or other studies are negative.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focal lesions are well demarcated and inhomogeneous on T1-weighted images. The earliest finding is a single-density line (low-intensity signal) that represents the separation of normal and ischemic bone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A second high-intensity line appears on T2-weighted images, representing hypervascular granulation tissue; this is the pathognomonic double-line sign  (
         <a class="graphic graphic_diagnosticimage graphicRef58502" href="/z/d/graphic/58502.html" rel="external">
          image 4
         </a>
         ) [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1005865292">
         <span class="h4">
          Limited role of radionuclide bone scanning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bone scans should not be used for the diagnosis of osteonecrosis. There is a high rate of false negatives (up to 25 percent) when using bone scans for the diagnosis of hip osteonecrosis [
         <a href="#rid101">
          101
         </a>
         ]. Moreover, bone scans are even less capable of diagnosing osteonecrosis of the shoulder, knee, and ankle. In selected cases, radionuclide bone scanning may be an alternative for patients in whom other cross-sectional imaging is contraindicated. Increased bone turnover at the junction of dead and reactive bone results in increased uptake surrounding a cold area; this has been called the doughnut sign [
         <a href="#rid105">
          105
         </a>
         ]. However, bone scanning, performed in 48 patients with suspected osteonecrosis of the shoulder, hip, knee, or ankle, was less sensitive than MRI (56 versus 100 percent) in diagnosing histologically confirmed osteonecrosis [
         <a href="#rid101">
          101
         </a>
         ]. Sensitivity was least in patients with early-stage lesions.
        </p>
        <p class="headingAnchor" id="H424085479">
         <span class="h3">
          Radiologic classification systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several different radiologic classification and staging systems, predominantly describing osteonecrosis of the hip, have been developed to provide information on the extent of disease and risk of progression, and thus, help guide treatment decisions [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3357682577">
         <span class="h4">
          Extent of disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The updated Association Research Circulation Osseous (ARCO) was developed to bring uniformity to classification of osteonecrosis [
         <a href="#rid107">
          107
         </a>
         ]. In the updated version, stage 0 was eliminated, stage III was subdivided into early (IIIA) and late (IIIB) stages depending on the degree of head depression (≤2 versus &gt;2 mm), and acetabular involvement was incorporated into stage IV:
        </p>
        <p>
         Precollapse:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage I – Normal radiograph, abnormal MRI findings
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage II – No crescent sign, radiographic evidence of sclerosis, osteolysis or focal osteoporosis
        </p>
        <p>
        </p>
        <p>
         Collapse:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage III – Subchondral fracture, fracture in the necrotic portion and/or flattening of the femoral head on radiograph or on radiograph or CT
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IIIA – Femoral head depression ≤ 2 mm
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IIIB – Femoral head depression &gt; 2 mm
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage IV – Evidence of osteoarthritis, joint space narrowing, degenerative acetabular change
        </p>
        <p>
        </p>
        <p>
         An earlier and occasionally used system is the Ficat staging system described by Ficat and Arlet [
         <a href="#rid106">
          106,108
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage 0 – No radiographic abnormalities
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage I – Slight abnormalities on radiograph
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage II – Sclerotic or cystic lesions
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IIA – No crescent sign
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IIB – Crescent sign without flattening
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage III – Flattening or subchondral collapse
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stage IV – Osteoarthritis with articular collapse
        </p>
        <p>
        </p>
        <p>
         Other classification systems have used additional imaging findings (eg, cross-sectional imaging, bone scans) to quantify involvement. As an example, the Steinberg staging system included findings on bone scan and MRI to address the importance of the size and extent of the lesion in the prognosis of various treatments [
         <a href="#rid109">
          109
         </a>
         ]. Other classification systems include the University of Pennsylvania staging system [
         <a href="#rid110">
          110,111
         </a>
         ] and the Japanese Orthopaedic Association System [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H687879139">
         <span class="h4">
          Risk of progression to collapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several morphologic features appear to be associated with a risk of collapse including lesion size and extent and location (eg, lateral pillar involvement) [
         <a href="#rid113">
          113
         </a>
         ]. Various methods using measurements from radiographic images (mainly MRI) have been proposed to help predict the risk of progression of femoral head collapse [
         <a href="#rid113">
          113
         </a>
         ]. The modified Kerboul combined necrotic angle is one method that is relatively easy to obtain. It is calculated by summing the arcs of necrosis on sagittal and coronal MR images  (
         <a class="graphic graphic_diagnosticimage graphicRef131122" href="/z/d/graphic/131122.html" rel="external">
          image 5
         </a>
         ). Combined necrotic angles less than 190 degrees, between 190 and 240 degrees, and greater than 240 degrees are associated with low, moderate, and high risks of femoral collapse, respectively [
         <a href="#rid114">
          114,115
         </a>
         ].
        </p>
        <p>
         A finite element analysis model to determine the von Mises stress distribution of the femoral head has also been studied, and a patient-specific model may become useful for estimating the risk of collapse; additional study is needed [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4215755221">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of pain with characteristics that suggest an osteoarticular origin and with imaging features compatible with osteonecrosis is discussed below.
        </p>
        <p>
         The general approach to the evaluation of site-specific pain (eg, hip, shoulder) is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1820.html" rel="external">
          "Monoarthritis in adults: Etiology and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1821.html" rel="external">
          "Evaluation of the adult with polyarticular pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/238.html" rel="external">
          "Evaluation of the adult with shoulder complaints"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/252.html" rel="external">
          "Approach to the adult with unspecified hip pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2856.html" rel="external">
          "Approach to hip pain in childhood"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/253.html" rel="external">
          "Approach to the adult with unspecified knee pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13793.html" rel="external">
          "Overview of foot anatomy and biomechanics and assessment of foot pain in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1830.html" rel="external">
          "History and examination of the adult with hand pain"
         </a>
         .)
        </p>
        <p>
         Bone pain as a manifestation of primary or metastatic tumor is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/91912.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6243.html" rel="external">
          "Overview of common presenting signs and symptoms of childhood cancer", section on 'Bone and joint pain'
         </a>
         .)
        </p>
        <p>
         Pain with ambulation and nocturnal limb pain or rest pain related to peripheral artery disease (PAD), which is distinguished through history (risk factors) and physical examination (diminished pulses), are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">
          "Clinical features and diagnosis of lower extremity peripheral artery disease"
         </a>
         .)
        </p>
        <p>
         There are a few specific variants of osteonecrosis that should also be taken into consideration. These are briefly discussed below and include bone marrow edema syndrome (BMES), subchondral insufficiency fracture, osteonecrosis during pregnancy, and idiopathic transient osteoporosis of the hip.
        </p>
        <p class="headingAnchor" id="H2918575473">
         <span class="h2">
          Bone marrow edema syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         BMES, also known as transient osteopenia of the hip (TOH), may occur in isolation or in association with injuries, particularly those that result in neurologic damage. In the latter situation, chronic pain and transient osteopenia are features of complex regional pain syndrome (also known as reflex sympathetic dystrophy, causalgia, and other terms). (See
         <a class="medical medical_review" href="/z/d/html/5628.html" rel="external">
          "Complex regional pain syndrome in adults: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         When the hip is affected by BMES, MRI findings suggestive of BMES (decreased signal on T1-weighted images and increased intensity on T2-weighted images) may extend from the femoral head into the femoral neck. An effusion may be present. The absence of fever, leukocytosis, or elevation of acute phase reactants (erythrocyte sedimentation rate [ESR] and/or C-reactive protein [CRP]) is characteristic of both osteonecrosis and BMES and helps to exclude an infectious etiology. (See
         <a class="medical medical_review" href="/z/d/html/1816.html" rel="external">
          "Imaging evaluation of the painful hip in adults", section on 'Bone marrow edema syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1934473570">
         <span class="h2">
          Subchondral insufficiency fracture
         </span>
         <span class="headingEndMark">
          —
         </span>
         A subchondral fracture of the femoral head typically occurs in patients with preexisting osteopenia and is thought, in most cases, to represent an insufficiency fracture. Such fractures may be difficult to visualize with plain radiographs. Subtle flattening is sometimes present with early lesions; collapse is progressive. Linear regions of low signal on both T1- and T2-weighted MRI in the subchondral area that parallel the articular surface are characteristic of these rare fractures [
         <a href="#rid117">
          117,118
         </a>
         ]. There is a growing recognition that most patients diagnosed with spontaneous osteonecrosis of the knee (sometimes called SPONK or SONK) actually have insufficiency fractures as well.
        </p>
        <p class="headingAnchor" id="H1046411824">
         <span class="h2">
          Osteonecrosis during pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteonecrosis of the femoral head during pregnancy is rare but can occur without any of the traditional risk factors for the disease. The clinical presentation and diagnosis of osteonecrosis of the hip during pregnancy is discussed in detail separately (see
         <a class="medical medical_review" href="/z/d/html/427.html" rel="external">
          "Maternal adaptations to pregnancy: Musculoskeletal changes and pain", section on 'Osteonecrosis of the femoral head'
         </a>
         ). Osteonecrosis of the hip during pregnancy can be confused with transient osteoporosis of the hip during pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/427.html" rel="external">
          "Maternal adaptations to pregnancy: Musculoskeletal changes and pain", section on 'Transient osteoporosis of the hip'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2101137620">
         <span class="h2">
          Idiopathic transient osteoporosis of the hip
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transient osteoporosis of the hip is a rare skeletal disorder that can occur in previously healthy young to middle-aged men, and during pregnancy [
         <a href="#rid119">
          119,120
         </a>
         ]. MRI of these patients typically shows edema into the femoral neck and metaphysis, which is not common with osteonecrosis. This disorder has a better prognosis than osteonecrosis during pregnancy and is typically self-limited. (See
         <a class="medical medical_review" href="/z/d/html/427.html" rel="external">
          "Maternal adaptations to pregnancy: Musculoskeletal changes and pain", section on 'Transient osteoporosis of the hip'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3990338681">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120098.html" rel="external">
          "Society guideline links: Osteonecrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3630101070">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17211.html" rel="external">
          "Patient education: Avascular necrosis of the hip (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H892925183">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Osteonecrosis is associated with numerous conditions and treatments that can cause direct damage to vasculature of the bone or direct and indirect injury to the bone or bone marrow, and ultimately mechanical failure of the bone. Osteonecrosis is also termed aseptic necrosis, avascular necrosis (AVN), atraumatic necrosis, and ischemic necrosis. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Risk factors for osteonecrosis include traumatic injury that disrupts the arterial supply to the bone, the use of certain medications or conditions that alter perfusion through otherwise normal vessels (eg, glucocorticoids, bisphosphonates, sickle cell disease, systemic lupus erythematosus [SLE], Gaucher disease [GD], thrombophilia, decompression disease), treatments that are toxic to bone marrow (eg, radiation therapy), and others that have multifactorial causes (eg, post-transplantation). (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Certain anatomic sites are prone to osteonecrosis and include the femoral head, the knee (distal femoral and proximal tibial condyles), humeral head, and certain bones of the foot (talus) and wrist (scaphoid), but any bone can be involved. (See
         <a class="local">
          'Clinical features and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Osteonecrosis can be asymptomatic or symptomatic. Patients with symptomatic osteonecrosis typically complain of pain associated with the affected site with and without activity, which, for the extremities, may limit activities of daily living or ambulation. (See
         <a class="local">
          'History and physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – For symptomatic patients, the initial evaluation of a patient with suspected osteonecrosis should begin with plain radiography of the affected site. If the history and physical examination are highly suggestive and plain radiography is not diagnostic, MRI of the affected joint should be performed. MRI is highly sensitive for osteonecrosis, and identifies pathologic changes earlier than other imaging modalities. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiologic classification systems
         </strong>
         – Several different radiologic classification and staging systems, predominantly describing osteonecrosis of the hip, have been developed to provide information on the extent of disease and risk of progression, and, thus, help guide treatment decisions. (See
         <a class="local">
          'Radiologic classification systems'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of osteonecrosis includes a variety of other entities that can cause bone or joint pain. Specific considerations for related but distinct entities that are considered variants of osteonecrosis, including bone marrow edema syndrome (BMES), subchondral insufficiency fracture, osteonecrosis during pregnancy, and idiopathic transient osteoporosis of the hip, are discussed above. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Koo KH, Kim R, Ko GH, et al. Preventing collapse in early osteonecrosis of the femoral head. A randomised clinical trial of core decompression. J Bone Joint Surg Br 1995; 77:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Min BW, Song KS, Cho CH, et al. Untreated asymptomatic hips in patients with osteonecrosis of the femoral head. Clin Orthop Relat Res 2008; 466:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moya-Angeler J, Gianakos AL, Villa JC, et al. Current concepts on osteonecrosis of the femoral head. World J Orthop 2015; 6:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326:1473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukushima W, Fujioka M, Kubo T, et al. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 2010; 468:2715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi S, Fukushima W, Yamamoto T, et al. Temporal Trends in Characteristics of Newly Diagnosed Nontraumatic Osteonecrosis of the Femoral Head From 1997 to 2011: A Hospital-Based Sentinel Monitoring System in Japan. J Epidemiol 2015; 25:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cui L, Zhuang Q, Lin J, et al. Multicentric epidemiologic study on six thousand three hundred and ninety five cases of femoral head osteonecrosis in China. Int Orthop 2016; 40:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995; 77:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang CC, Greenspan A, Gershwin ME. Osteonecrosis: current perspectives on pathogenesis and treatment. Semin Arthritis Rheum 1993; 23:47.
          </a>
         </li>
         <li class="breakAll">
          Yamamoto T. The Pathology of Osteonecrosis of the Femoral Head. In: Ostenecrosis, Koo KH, Mont MA, Jones LC (Eds), Springer-Verlag, Berlin Heidelberg 2014. p.151.
         </li>
         <li class="breakAll">
          Koo KH, Lee YK, Lee YJ. Pathophysiology of Ischemic Diseases of the Hip: Osteonecrosis, Borderline Necrosis, and Bone Marrow Edema Syndrome. In: Osteonecrosis, Koo KH, Mont MA, Jones LC (Eds), Springer-Verlag, Berlin Heidelberg 2014. p.143.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radke S, Battmann A, Jatzke S, et al. Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteonecrosis of the femoral head. J Orthop Res 2006; 24:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang P, Jergesen HE, Moseley ME, et al. Avascular necrosis of the femoral head: high-field-strength MR imaging with histologic correlation. Radiology 1988; 169:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munk PL, Helms CA, Holt RG. Immature bone infarcts: findings on plain radiographs and MR scans. AJR Am J Roentgenol 1989; 152:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah KN, Racine J, Jones LC, Aaron RK. Pathophysiology and risk factors for osteonecrosis. Curr Rev Musculoskelet Med 2015; 8:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shigemura T, Nakamura J, Kishida S, et al. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatology (Oxford) 2011; 50:2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Chaudhry-Ahluwalia V, Ibañez D, et al. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol 2001; 28:2226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamen DL, Alele JD. Skeletal manifestations of systemic autoimmune diseases. Curr Opin Endocrinol Diabetes Obes 2010; 17:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang A, Ren M, Wang J. The pathogenesis of steroid-induced osteonecrosis of the femoral head: A systematic review of the literature. Gene 2018; 671:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones JP Jr. Fat embolism and osteonecrosis. Orthop Clin North Am 1985; 16:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon L. Idiopathic necrosis of the femoral head: pathogenesis and treatment. Can J Surg 1981; 24:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishimura T, Matsumoto T, Nishino M, Tomita K. Histopathologic study of veins in steroid treated rabbits. Clin Orthop Relat Res 1997; :37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koo KH, Kim R, Kim YS, et al. Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin Rheumatol 2002; 21:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu LH, Zhang QY, Sun W, et al. Corticosteroid-induced Osteonecrosis of the Femoral Head: Detection, Diagnosis, and Treatment in Earlier Stages. Chin Med J (Engl) 2017; 130:2601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vreden SG, Hermus AR, van Liessum PA, et al. Aseptic bone necrosis in patients on glucocorticoid replacement therapy. Neth J Med 1991; 39:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mont MA, Pivec R, Banerjee S, et al. High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review. J Arthroplasty 2015; 30:1506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dilisio MF. Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based study of 24 million patients. Orthopedics 2014; 37:e631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zizic TM, Marcoux C, Hungerford DS, et al. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985; 79:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagasawa K, Tada Y, Koarada S, et al. Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 2005; 14:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abeles M, Urman JD, Rothfield NF. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 1978; 138:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuo K, Hirohata T, Sugioka Y, et al. Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 1988; :115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shigemura T, Nakamura J, Kishida S, et al. The incidence of alcohol-associated osteonecrosis of the knee is lower than the incidence of steroid-associated osteonecrosis of the knee: an MRI study. Rheumatology (Oxford) 2012; 51:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon BH, Kim TY, Shin IS, et al. Alcohol intake and the risk of osteonecrosis of the femoral head in Japanese populations: a dose-response meta-analysis of case-control studies. Clin Rheumatol 2017; 36:2517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen Z, Lin Z, Yan W, Zhang J. Influence of cigarette smoking on osteonecrosis of the femoral head (ONFH): a systematic review and meta-analysis. Hip Int 2017; 27:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedri H, Cherif M, Zouaghi K, et al. Avascular osteonecrosis after renal transplantation. Transplant Proc 2007; 39:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marston SB, Gillingham K, Bailey RF, Cheng EY. Osteonecrosis of the femoral head after solid organ transplantation: a prospective study. J Bone Joint Surg Am 2002; 84:2145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elmstedt E, Svahn T. Skeletal complications following renal transplantation. Acta Orthop Scand 1981; 52:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E. Bone disease after renal transplantation. Clin J Am Soc Nephrol 2006; 1:1300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shibatani M, Fujioka M, Arai Y, et al. Degree of corticosteroid treatment within the first 2 months of renal transplantation has a strong influence on the incidence of osteonecrosis of the femoral head. Acta Orthop 2008; 79:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakai T, Sugano N, Kokado Y, et al. Tacrolimus may be associated with lower osteonecrosis rates after renal transplantation. Clin Orthop Relat Res 2003; :163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nehme D, Rondeau E, Paillard F, et al. Aseptic necrosis of bone following renal transplantation: relation with hyperparathyroidism. Nephrol Dial Transplant 1989; 4:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McClune B, Majhail NS, Flowers ME. Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Semin Hematol 2012; 49:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulte CM, Beelen DW. Low pretransplant bone-mineral density and rapid bone loss do not increase risk for avascular osteonecrosis after allogeneic hematopoietic stem cell transplantation. Transplantation 2005; 79:1748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tauchmanovà L, De Rosa G, Serio B, et al. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer 2003; 97:2453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAvoy S, Baker KS, Mulrooney D, et al. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulte CM, Beelen DW. Avascular osteonecrosis after allogeneic hematopoietic stem-cell transplantation: diagnosis and gender matter. Transplantation 2004; 78:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimant J, Ginzler EM, Diamond HS, et al. Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. J Rheumatol 1978; 5:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oinuma K, Harada Y, Nawata Y, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001; 60:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladman DD, Dhillon N, Su J, Urowitz MB. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors. Lupus 2018; 27:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugano N, Ohzono K, Masuhara K, et al. Prognostication of osteonecrosis of the femoral head in patients with systemic lupus erythematosus by magnetic resonance imaging. Clin Orthop Relat Res 1994; :190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aranow C, Zelicof S, Leslie D, et al. Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol 1997; 24:2318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mont MA, Glueck CJ, Pacheco IH, et al. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 1997; 24:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asherson RA, Lioté F, Page B, et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1993; 20:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 2000; 59:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones LC, Mont MA, Le TB, et al. Procoagulants and osteonecrosis. J Rheumatol 2003; 30:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gómez-Puerta JA, Peris P, Reverter JC, et al. High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature. Medicine (Baltimore) 2013; 92:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasoo S, Sangle S, Zain M, et al. Orthopaedic manifestations of the antiphospholipid (Hughes) syndrome. Lupus 2005; 14:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Large TM, Adams MR, Loeffler BJ, Gardner MJ. Posttraumatic Avascular Necrosis After Proximal Femur, Proximal Humerus, Talar Neck, and Scaphoid Fractures. J Am Acad Orthop Surg 2019; 27:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slobogean GP, Sprague SA, Scott T, Bhandari M. Complications following young femoral neck fractures. Injury 2015; 46:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu J, Zhang C, Wang T. Avascular necrosis in proximal humeral fractures in patients treated with operative fixation: a meta-analysis. J Orthop Surg Res 2014; 9:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodd A, Lefaivre KA. Outcomes of Talar Neck Fractures: A Systematic Review and Meta-analysis. J Orthop Trauma 2015; 29:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallier HA, Reichard SG, Boyd AJ, Moore TA. A new look at the Hawkins classification for talar neck fractures: which features of injury and treatment are predictive of osteonecrosis? J Bone Joint Surg Am 2014; 96:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adesina O, Brunson A, Keegan THM, Wun T. Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California. Blood Adv 2017; 1:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flouzat-Lachaniete CH, Roussignol X, Poignard A, et al. Multifocal joint osteonecrosis in sickle cell disease. Open Orthop J 2009; 3:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamath AF, McGraw MH, Israelite CL. Surgical management of osteonecrosis of the femoral head in patients with sickle cell disease. World J Orthop 2015; 6:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linari S, Castaman G. Clinical manifestations and management of Gaucher disease. Clin Cases Miner Bone Metab 2015; 12:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baris HN, Cohen IJ, Mistry PK. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. Pediatr Endocrinol Rev 2014; 12 Suppl 1:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dussen L, Biegstraaten M, Dijkgraaf MG, Hollak CE. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet J Rare Dis 2014; 9:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mistry PK, Deegan P, Vellodi A, et al. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 2009; 147:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu YF, Chen WM, Lin YF, et al. Type II collagen gene variants and inherited osteonecrosis of the femoral head. N Engl J Med 2005; 352:2294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su P, Li R, Liu S, et al. Age at onset-dependent presentations of premature hip osteoarthritis, avascular necrosis of the femoral head, or Legg-Calvé-Perthes disease in a single family, consequent upon a p.Gly1170Ser mutation of COL2A1. Arthritis Rheum 2008; 58:1701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyamoto Y, Matsuda T, Kitoh H, et al. A recurrent mutation in type II collagen gene causes Legg-Calvé-Perthes disease in a Japanese family. Hum Genet 2007; 121:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zalavras CG, Vartholomatos G, Dokou E, Malizos KN. Factor V Leiden and prothrombin gene mutations in femoral head osteonecrosis. Thromb Haemost 2002; 87:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arruda VR, Belangero WD, Ozelo MC, et al. Inherited risk factors for thrombophilia among children with Legg-Calvé-Perthes disease. J Pediatr Orthop 1999; 19:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Björkman A, Svensson PJ, Hillarp A, et al. Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res 2004; :168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Björkman A, Burtscher IM, Svensson PJ, et al. Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg 2005; 125:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim TH, Baek SH, Lim JO, et al. Genetic variation in the coagulation factor V gene and risk of femoral head osteonecrosis. Mol Med Rep 2015; 12:4434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyanishi K, Kamo Y, Ihara H, et al. Risk factors for dysbaric osteonecrosis. Rheumatology (Oxford) 2006; 45:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharareh B, Schwarzkopf R. Dysbaric osteonecrosis: a literature review of pathophysiology, clinical presentation, and management. Clin J Sport Med 2015; 25:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunstreich M, Kummer S, Laws HJ, et al. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica 2016; 101:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heneghan MB, Rheingold SR, Li Y, et al. Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 2016; 16:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niinimäki R, Hansen LM, Niinimäki T, et al. Incidence of Severe Osteonecrosis Requiring Total Joint Arthroplasty in Children and Young Adults Treated for Leukemia or Lymphoma: A Nationwide, Register-Based Study in Finland and Denmark. J Adolesc Young Adult Oncol 2013; 2:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol 2010; 11:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown P, Crane L. Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature. Clin Infect Dis 2001; 32:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morse CG, Mican JM, Jones EC, et al. The incidence and natural history of osteonecrosis in HIV-infected adults. Clin Infect Dis 2007; 44:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brechtl JR, Breitbart W, Galietta M, et al. The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manage 2001; 21:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitlock GG, Herbert S, Copas A, et al. Avascular necrosis in HIV patients: a case-control study. Int J STD AIDS 2013; 24:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin K, Lawson-Ayayi S, Miremont-Salamé G, et al. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002). HIV Med 2004; 5:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cetik O, Cift H, Comert B, Cirpar M. Risk of osteonecrosis of the femoral condyle after arthroscopic chondroplasty using radiofrequency: a prospective clinical series. Knee Surg Sports Traumatol Arthrosc 2009; 17:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karim AR, Cherian JJ, Jauregui JJ, et al. Osteonecrosis of the knee: review. Ann Transl Med 2015; 3:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zywiel MG, McGrath MS, Seyler TM, et al. Osteonecrosis of the knee: a review of three disorders. Orthop Clin North Am 2009; 40:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zizic TM, Marcoux C, Hungerford DS, Stevens MB. The early diagnosis of ischemic necrosis of bone. Arthritis Rheum 1986; 29:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaPorte DM, Mont MA, Mohan V, et al. Multifocal osteonecrosis. J Rheumatol 1998; 25:1968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lespasio MJ, Sodhi N, Mont MA. Osteonecrosis of the Hip: A Primer. Perm J 2019; 23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etienne G, Mont MA, Ragland PS. The diagnosis and treatment of nontraumatic osteonecrosis of the femoral head. Instr Course Lect 2004; 53:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amanatullah DF, Strauss EJ, Di Cesare PE. Current management options for osteonecrosis of the femoral head: part 1, diagnosis and nonoperative management. Am J Orthop (Belle Mead NJ) 2011; 40:E186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphey MD, Roberts CC, Bencardino JT, et al. ACR Appropriateness Criteria Osteonecrosis of the Hip. J Am Coll Radiol 2016; 13:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens K, Tao C, Lee SU, et al. Subchondral fractures in osteonecrosis of the femoral head: comparison of radiography, CT, and MR imaging. AJR Am J Roentgenol 2003; 180:363.
          </a>
         </li>
         <li class="breakAll">
          Mazieres B. Osteonecrosis. In: Rheumatology, Hochberg MC, Silman AJ, Smolen JS, et al. (Eds), Mosby, London 2003. p.1877.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mont MA, Ulrich SD, Seyler TM, et al. Bone scanning of limited value for diagnosis of symptomatic oligofocal and multifocal osteonecrosis. J Rheumatol 2008; 35:1629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markisz JA, Knowles RJ, Altchek DW, et al. Segmental patterns of avascular necrosis of the femoral heads: early detection with MR imaging. Radiology 1987; 162:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zibis AH, Varitimidis SE, Dailiana ZH, et al. Fast sequences MR imaging at the investigation of painful skeletal sites in patients with hip osteonecrosis. Springerplus 2015; 4:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerra JJ, Steinberg ME. Distinguishing transient osteoporosis from avascular necrosis of the hip. J Bone Joint Surg Am 1995; 77:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumont M, Danais S, Taillefer R. "Doughnut" sign in avascular necrosis of the bone. Clin Nucl Med 1984; 9:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sultan AA, Mohamed N, Samuel LT, et al. Classification systems of hip osteonecrosis: an updated review. Int Orthop 2019; 43:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon BH, Mont MA, Koo KH, et al. The 2019 Revised Version of Association Research Circulation Osseous Staging System of Osteonecrosis of the Femoral Head. J Arthroplasty 2020; 35:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg Br 1985; 67:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg ME, Bands RE, Parry S, et al. Does lesion size affect the outcome in avascular necrosis? Clin Orthop Relat Res 1999; :262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Joint Surg Br 1995; 77:34.
          </a>
         </li>
         <li class="breakAll">
          Steinberg DR, Steinberg ME. The University of Pennsylvania Classification of Osteonecrosis. In: Osteonecrosis, Koo KH, Mont MA, Jones LC (Eds), Springer, Heidelberg 2014. p.201.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugano N, Atsumi T, Ohzono K, et al. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J Orthop Sci 2002; 7:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg ME, Oh SC, Khoury V, et al. Lesion size measurement in femoral head necrosis. Int Orthop 2018; 42:1585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ha YC, Jung WH, Kim JR, et al. Prediction of collapse in femoral head osteonecrosis: a modified Kerboul method with use of magnetic resonance images. J Bone Joint Surg Am 2006; 88 Suppl 3:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koo KH, Kim R. Quantifying the extent of osteonecrosis of the femoral head. A new method using MRI. J Bone Joint Surg Br 1995; 77:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen PF, Guo WS, Zhang QD, et al. Significance of Lateral Pillar in Osteonecrosis of Femoral Head: A Finite Element Analysis. Chin Med J (Engl) 2017; 130:2569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies M, Cassar-Pullicino VN, Darby AJ. Subchondral insufficiency fractures of the femoral head. Eur Radiol 2004; 14:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto T, Bullough PG. The role of subchondral insufficiency fracture in rapid destruction of the hip joint: a preliminary report. Arthritis Rheum 2000; 43:2423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balakrishnan A, Schemitsch EH, Pearce D, McKee MD. Distinguishing transient osteoporosis of the hip from avascular necrosis. Can J Surg 2003; 46:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lakhanpal S, Ginsburg WW, Luthra HS, Hunder GG. Transient regional osteoporosis. A study of 56 cases and review of the literature. Ann Intern Med 1987; 106:444.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 122049 Version 9.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7593097" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Preventing collapse in early osteonecrosis of the femoral head. A randomised clinical trial of core decompression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18327630" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Untreated asymptomatic hips in patients with osteonecrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26396935" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Current concepts on osteonecrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1574093" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Nontraumatic necrosis of bone (osteonecrosis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20224959" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25912097" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Temporal Trends in Characteristics of Newly Diagnosed Nontraumatic Osteonecrosis of the Femoral Head From 1997 to 2011: A Hospital-Based Sentinel Monitoring System in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26660727" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Multicentric epidemiologic study on six thousand three hundred and ninety five cases of femoral head osteonecrosis in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7890797" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Non-traumatic avascular necrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8235665" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Osteonecrosis: current perspectives on pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8235665" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Osteonecrosis: current perspectives on pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8235665" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Osteonecrosis: current perspectives on pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16609965" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteonecrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3175001" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Avascular necrosis of the femoral head: high-field-strength MR imaging with histologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2783808" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Immature bone infarcts: findings on plain radiographs and MR scans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26142896" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pathophysiology and risk factors for osteonecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21865285" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11669161" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20962632" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Skeletal manifestations of systemic autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29859289" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The pathogenesis of steroid-induced osteonecrosis of the femoral head: A systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3903602" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Fat embolism and osteonecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7326618" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Idiopathic necrosis of the femoral head: pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9005894" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Histopathologic study of veins in steroid treated rabbits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12189457" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29067959" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Corticosteroid-induced Osteonecrosis of the Femoral Head: Detection, Diagnosis, and Treatment in Earlier Stages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1791877" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Aseptic bone necrosis in patients on glucocorticoid replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25900167" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24992058" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based study of 24 million patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4061472" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15934439" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/646538" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3409564" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22179736" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The incidence of alcohol-associated osteonecrosis of the knee is lower than the incidence of steroid-associated osteonecrosis of the knee: an MRI study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28685377" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Alcohol intake and the risk of osteonecrosis of the femoral head in Japanese populations: a dose-response meta-analysis of case-control studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28574127" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Influence of cigarette smoking on osteonecrosis of the femoral head (ONFH): a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17524885" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Avascular osteonecrosis after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12473701" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Osteonecrosis of the femoral head after solid organ transplantation: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7025559" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Skeletal complications following renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699362" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Bone disease after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18839369" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Degree of corticosteroid treatment within the first 2 months of renal transplantation has a strong influence on the incidence of osteonecrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14612643" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Tacrolimus may be associated with lower osteonecrosis rates after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2540458" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Aseptic necrosis of bone following renal transplantation: relation with hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22221785" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15973180" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Low pretransplant bone-mineral density and rapid bone loss do not increase risk for avascular osteonecrosis after allogeneic hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12733144" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20302963" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15480174" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Avascular osteonecrosis after allogeneic hematopoietic stem-cell transplantation: diagnosis and gender matter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/671430" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11709458" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28530464" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8050228" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Prognostication of osteonecrosis of the femoral head in patients with systemic lupus erythematosus by magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9415635" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinically occult avascular necrosis of the hip in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9101497" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Risk factors for osteonecrosis in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8474066" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10834864" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12672200" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Procoagulants and osteonecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24145698" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15934432" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Orthopaedic manifestations of the antiphospholipid (Hughes) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31149969" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Posttraumatic Avascular Necrosis After Proximal Femur, Proximal Humerus, Talar Neck, and Scaphoid Fractures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25480307" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Complications following young femoral neck fractures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24767176" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Avascular necrosis in proximal humeral fractures in patients treated with operative fixation: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25635362" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Outcomes of Talar Neck Fractures: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24500580" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A new look at the Hawkins classification for talar neck fractures: which features of injury and treatment are predictive of osteonecrosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29296770" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19572037" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Multifocal joint osteonecrosis in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26601059" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Surgical management of osteonecrosis of the femoral head in patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26604942" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical manifestations and management of Gaucher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25345088" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25056340" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19732054" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15930420" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Type II collagen gene variants and inherited osteonecrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18512791" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Age at onset-dependent presentations of premature hip osteoarthritis, avascular necrosis of the femoral head, or Legg-Calvé-Perthes disease in a single family, consequent upon a p.Gly1170Ser mutation of COL2A1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17394019" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A recurrent mutation in type II collagen gene causes Legg-Calvé-Perthes disease in a Japanese family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12083492" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Factor V Leiden and prothrombin gene mutations in femoral head osteonecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9890294" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Inherited risk factors for thrombophilia among children with Legg-Calvé-Perthes disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15292803" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15723247" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26130054" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Genetic variation in the coagulation factor V gene and risk of femoral head osteonecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16436490" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Risk factors for dysbaric osteonecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24662571" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Dysbaric osteonecrosis: a literature review of pathophysiology, clinical presentation, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27742768" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Osteonecrosis in children with acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27021949" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24380033" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Incidence of Severe Osteonecrosis Requiring Total Joint Arthroplasty in Children and Young Adults Treated for Leukemia or Lymphoma: A Nationwide, Register-Based Study in Finland and Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20947430" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Glucocorticoid use in acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11283813" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17278070" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The incidence and natural history of osteonecrosis in HIV-infected adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093241" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : High prevalence of osteonecrosis of the femoral head in HIV-infected adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11223313" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23970592" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Avascular necrosis in HIV patients: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15544694" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18758748" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Risk of osteonecrosis of the femoral condyle after arthroscopic chondroplasty using radiofrequency: a prospective clinical series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25705638" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Osteonecrosis of the knee: review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19358905" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Osteonecrosis of the knee: a review of three disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3768054" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The early diagnosis of ischemic necrosis of bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9779852" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Multifocal osteonecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30939270" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Osteonecrosis of the Hip: A Primer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15116601" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The diagnosis and treatment of nontraumatic osteonecrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22022684" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Current management options for osteonecrosis of the femoral head: part 1, diagnosis and nonoperative management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26846390" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : ACR Appropriateness Criteria Osteonecrosis of the Hip.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12540435" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Subchondral fractures in osteonecrosis of the femoral head: comparison of radiography, CT, and MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12540435" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Subchondral fractures in osteonecrosis of the femoral head: comparison of radiography, CT, and MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18528962" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Bone scanning of limited value for diagnosis of symptomatic oligofocal and multifocal osteonecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3809485" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Segmental patterns of avascular necrosis of the femoral heads: early detection with MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25674490" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Fast sequences MR imaging at the investigation of painful skeletal sites in patients with hip osteonecrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7713981" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Distinguishing transient osteoporosis from avascular necrosis of the hip.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6697617" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : "Doughnut" sign in avascular necrosis of the bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29916002" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Classification systems of hip osteonecrosis: an updated review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31866252" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : The 2019 Revised Version of Association Research Circulation Osseous Staging System of Osteonecrosis of the Femoral Head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3155745" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10546624" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Does lesion size affect the outcome in avascular necrosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7822393" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A quantitative system for staging avascular necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7822393" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : A quantitative system for staging avascular necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12355139" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29691613" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Lesion size measurement in femoral head necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17079365" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Prediction of collapse in femoral head osteonecrosis: a modified Kerboul method with use of magnetic resonance images.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7593098" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Quantifying the extent of osteonecrosis of the femoral head. A new method using MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29067956" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Significance of Lateral Pillar in Osteonecrosis of Femoral Head: A Finite Element Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12851782" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Subchondral insufficiency fractures of the femoral head.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11083264" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The role of subchondral insufficiency fracture in rapid destruction of the hip joint: a preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12812240" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Distinguishing transient osteoporosis of the hip from avascular necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3813239" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Transient regional osteoporosis. A study of 56 cases and review of the literature.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
